EndoSign® Capsule Sponge Devise and Diagnostic Report

Concepts

• taunton
• pathology services
• diagnostic service
• diagnostic services
• diagnostic report
• ® capsule sponge devise
• report
• sponge
• capsule
• endosign

Location

Somerset NHS Foundation Trust Sites

Description

Provision of consumables and diagnostic service for detecting Barrett's esophagus. This is an introduction of a non-invasive procedure to deliver benefits to patients including earlier detection and improved outcomes.

Total Quantity or Scope

By introducing a non-invasive procedure, the aim is to deliver significant benefits to patients, including earlier detection, reduced waiting times, and improved outcomes.The Trust plans to enter into a 12-month contract with a single supplier capable of providing both consumables and diagnostic services as an integrated solution. This initiative is not a product trial but rather a pilot project to assess the Trust's capacity and capability for long-term service delivery and will include a 12 month extension option. This is a notice with the intention to award a contract under the most suitable provider process. This is a new service, with a new provider and the contract is expected to be live between November 2025 and October 2026. The expected lifetime value of the contract is £316,848.00.

Award Detail

Award Criteria

CPV Codes

• 85111800 - Pathology services
• 33140000 - Medical consumables

Indicators

• Award on basis of price and quality.

Legal Justification

This is a Provider Selection Regime (PSR) intention to award notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award. The publication of this notice marks the start of the standstill period. Representations by providers must be made to the relevant authority by midnight on 29 October 2025. This contract has not yet formally been awarded; this notice serves as an intention to award under the PSR'.

Other Information

This is a Provider Selection Regime (PSR) confirmation of contract award notice. This contract has been awarded under the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award.The decision makers were: Cancer Programme ManagerNo conflicts of interest were declared among decision makers.The key criteria were weighted as follows:25% quality and Innovation20% Value20% Integration, Collaboration and Service Sustainability25% Improving access, reducing health inequalities and facilitating choice10% Social valueThe highest weightings have been applied to ensure a high quality, safe and effective services that are fully integrated in the healthcare system and that provide improved access, reduce health inequalities and facilitate chouse. These are the most important elements of the service.Value for money is also an important element to ensure the service can be provided to as many patients as possible to minimise waiting times.The rationale for choosing the provider with reference to the key criteria:The supplier selected is the only one who is able to provide both the capsule sponge and testing as one solution. The pathology element is proprietary to the supplier selected.